Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: DZOO who wrote (1414)	1/8/1998 12:02:00 PM
From: aknahow	Read Replies (1) \| Respond to of 1762

Interesting measure of Rituxans value. Xoma just sold it royalty interest in this product from (IDPH/GEN) for $17 million. If one assumes the royalty was 2% then the remaining present value is $833 million. Don't know how this would be split between IDPH and GEN. If the royalty was above 2%, the total value is less. Again this is just a start of getting a fix on the value of this product. No the sales of the product butthe earnings. It also is not 100% certain that the $17 million purchased Xomas entire royalty stream, (think so but wording creats doubts). Don't forget if you have any opinion on XOMA, even negative please post on the XOMA S.I. thread.